Advertisement
U.S. markets close in 34 minutes
  • S&P 500

    5,263.69
    +15.20 (+0.29%)
     
  • Dow 30

    39,857.72
    +97.64 (+0.25%)
     
  • Nasdaq

    16,407.43
    +7.91 (+0.05%)
     
  • Russell 2000

    2,124.11
    +9.76 (+0.46%)
     
  • Crude Oil

    83.07
    +1.72 (+2.11%)
     
  • Gold

    2,241.90
    +29.20 (+1.32%)
     
  • Silver

    24.97
    +0.22 (+0.88%)
     
  • EUR/USD

    1.0790
    -0.0040 (-0.37%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2622
    -0.0016 (-0.12%)
     
  • USD/JPY

    151.3950
    +0.1490 (+0.10%)
     
  • Bitcoin USD

    70,737.27
    +1,974.52 (+2.87%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Did Business Growth Power Apellis Pharmaceuticals' (NASDAQ:APLS) Share Price Gain of 277%?

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But in contrast you can make much more than 100% if the company does well. To wit, the Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) share price has flown 277% in the last three years. How nice for those who held the stock! It's also good to see the share price up 27% over the last quarter.

See our latest analysis for Apellis Pharmaceuticals

Apellis Pharmaceuticals wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

earnings-and-revenue-growth
earnings-and-revenue-growth

Apellis Pharmaceuticals is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. So we recommend checking out this free report showing consensus forecasts

A Different Perspective

Pleasingly, Apellis Pharmaceuticals' total shareholder return last year was 147%. That's better than the annualized TSR of 56% over the last three years. Given the track record of solid returns over varying time frames, it might be worth putting Apellis Pharmaceuticals on your watchlist. It's always interesting to track share price performance over the longer term. But to understand Apellis Pharmaceuticals better, we need to consider many other factors. For example, we've discovered 3 warning signs for Apellis Pharmaceuticals that you should be aware of before investing here.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Advertisement